Charles Schwab Investment Management Inc. Boosts Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Charles Schwab Investment Management Inc. lifted its position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 23.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 622,409 shares of the company's stock after acquiring an additional 119,616 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.66% of Scholar Rock worth $26,901,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new position in shares of Scholar Rock in the third quarter worth about $202,000. Fisher Asset Management LLC grew its stake in Scholar Rock by 593.6% in the 3rd quarter. Fisher Asset Management LLC now owns 734,019 shares of the company's stock valued at $5,879,000 after buying an additional 628,186 shares in the last quarter. FMR LLC grew its stake in Scholar Rock by 3.1% in the 3rd quarter. FMR LLC now owns 10,196,046 shares of the company's stock valued at $81,670,000 after buying an additional 308,813 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Scholar Rock by 900.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 36,331 shares of the company's stock valued at $291,000 after acquiring an additional 32,700 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Scholar Rock by 7.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company's stock worth $759,000 after acquiring an additional 6,269 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company's stock.

Remove Ads

Scholar Rock Trading Down 1.6 %

SRRK stock traded down $0.54 during midday trading on Friday, hitting $33.11. The company had a trading volume of 786,341 shares, compared to its average volume of 1,152,077. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 52 week low of $6.76 and a 52 week high of $46.98. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of -14.09 and a beta of 0.59. The stock's 50 day moving average price is $38.89 and its 200 day moving average price is $31.88.

Analyst Ratings Changes

SRRK has been the topic of a number of recent research reports. Wedbush reissued an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a report on Monday. HC Wainwright boosted their price target on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Finally, Truist Financial lifted their price target on Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday, November 25th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $40.86.

Insider Activity at Scholar Rock

In related news, insider Jing L. Marantz sold 5,655 shares of the firm's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $249,951.00. Following the sale, the insider now directly owns 67,200 shares of the company's stock, valued at $2,970,240. This trade represents a 7.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mo Qatanani sold 68,510 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the transaction, the insider now directly owns 111,084 shares of the company's stock, valued at $4,154,541.60. The trade was a 38.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 293,272 shares of company stock worth $11,030,778 in the last three months. 19.20% of the stock is owned by insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.